Biden Era Ushers In New Breed of Clean-Energy Profit-Stocks
With oil drilling and fracking now dead money, investors are driving Green-Energy stocks to dizzying heights and getting rich along the way. Here’s a brand new clean energy innovator, currently undiscovered at $2 per share, that’s deploying a world’s-first business model with 10X to 20X upside.
Get the details here...
pixel

YMAB Insider Trading (Y-mAbs Therapeutics)

Insider Ownership Percentage: 38.40%
Insider Buying (Last 12 Months): $78,853.35
Insider Selling (Last 12 Months): $18,751,936.75

Y-mAbs Therapeutics Insider Trading History Chart

Y-mAbs Therapeutics Share Price & Price History

$26.38
▼ -2.11 (-7.41%)
As of 04/9/2021 01:00 AM ET
Days: 30 | 90 | 365
Gain the Knowledge You Need to Successfully Trade Futures Markets
Our Technical Analysis Guide will give you the insight into today’s fast-moving markets. It’s designed to give you a head start in learning the basics of various TA tools and techniques.
Download Your Complimentary Technical Analysis Guide TODAY!
pixel

Y-mAbs Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/15/2021Thomas GadInsiderSell7,000$36.79$257,530.007,000  
1/19/2021David N GillDirectorSell2,000$46.52$93,040.002,000  
1/19/2021Thomas GadInsiderSell7,000$46.51$325,570.007,000  
1/5/2021Thomas GadInsiderSell7,000$49.36$345,520.007,000  
12/28/2020Thomas GadInsiderSell7,000$51.98$363,860.007,000  
12/16/2020Thomas GadInsiderSell7,000$53.01$371,070.007,000  
12/14/2020Thomas GadInsiderSell4,000$52.89$211,560.00  
12/10/2020Thomas GadInsiderSell50,000$50.75$2,537,500.0050,000  
12/2/2020Pedro Claus Juan Moller-SanCEOSell40,734$51.27$2,088,432.1815,625  
12/2/2020Vignesh RajahCMOBuy233$51.03$11,889.99  
12/1/2020Thomas GadChairmanSell4,000$51.42$205,680.00  
11/17/2020Vignesh RajahCMOBuy1,464$45.74$66,963.36  
11/3/2020David N GillDirectorSell4,000$45.00$180,000.004,000  
10/15/2020Thomas GadChairmanSell4,000$39.15$156,600.00  
10/1/2020Thomas GadChairmanSell4,000$38.88$155,520.00  
9/14/2020Thomas GadChairmanSell22,569$41.00$925,329.0013,860  
9/11/2020Thomas GadChairmanSell13,571$40.33$547,318.4313,860  
9/1/2020Thomas GadChairmanSell4,000$41.60$166,400.00  
8/17/2020Thomas GadChairmanSell4,000$40.35$161,400.00  
8/11/2020Thomas GadChairmanSell37,000$40.06$1,482,220.00  
7/15/2020Thomas GadChairmanSell4,000$40.06$160,240.00  
6/15/2020Thomas GadChairmanSell4,000$43.45$173,800.00  
6/4/2020Thomas GadChairmanSell4,000$41.61$166,440.00  
5/26/2020Mahiuddin AhmedVPSell50,000$39.38$1,969,000.00150,000  
5/13/2020Bo KruseCFOSell14,724$37.86$557,450.64285,276  
5/13/2020Pedro Claus Juan Moller-SanCEOSell60,846$37.75$2,296,936.5015,625  
5/12/2020Mahiuddin AhmedVPSell20,000$39.19$783,800.00240,000  
5/12/2020Thomas GadChairmanSell50,000$39.04$1,952,000.00  
4/13/2020Thomas GadChairmanSell4,000$29.43$117,720.00  
3/17/2020Pedro Claus Juan Moller-SanCEOBuy1,900$17.22$32,718.0015,625  
3/16/2020Thomas GadChairmanSell4,000$18.01$72,040.00  
2/10/2020Thomas GadChairmanSell4,000$33.03$132,120.00  
1/27/2020Thomas GadChairmanSell4,000$35.06$140,240.00  
1/13/2020Thomas GadChairmanSell4,000$30.90$123,600.00  
12/16/2019Thomas GadChairmanSell4,000$31.54$126,160.00  
12/2/2019Thomas GadChairmanSell4,000$32.48$129,920.00  
11/18/2019Thomas GadChairmanSell4,000$28.85$115,400.00
11/4/2019Thomas GadChairmanSell4,000$30.01$120,040.00
10/30/2019James HealyDirectorBuy90,000$29.79$2,681,100.00
10/21/2019Thomas GadChairmanSell4,000$31.65$126,600.00
10/18/2019Thomas GadCEOSell7,250$16.71$121,147.50
10/7/2019Thomas GadChairmanSell4,000$25.21$100,840.00
9/16/2019Thomas GadChairmanSell4,000$30.59$122,360.00
9/6/2019Johan Wedell-WedellsborgDirectorSell17,243$27.00$465,561.00
9/3/2019Thomas GadChairmanSell4,000$25.77$103,080.00  
8/30/2019Johan Wedell-WedellsborgDirectorSell89,166$26.58$2,370,032.28  
8/28/2019Johan Wedell-WedellsborgDirectorSell49,357$27.08$1,336,587.56  
8/21/2019Johan Wedell-WedellsborgDirectorSell168,244$27.57$4,638,487.08  
8/19/2019Thomas GadInsiderSell4,000$27.70$110,800.00  
8/5/2019Thomas GadInsiderSell4,000$21.78$87,120.00  
7/22/2019Thomas GadInsiderSell4,000$22.54$90,160.00  
7/8/2019Thomas GadInsiderSell4,000$22.40$89,600.00  
6/24/2019Thomas GadInsiderSell4,000$21.77$87,080.00  
6/10/2019Thomas GadInsiderSell4,000$22.79$91,160.00  
6/3/2019Thomas GadInsiderSell4,000$20.03$80,120.00  
5/28/2019Thomas GadInsiderSell6,000$20.21$121,260.00  
5/13/2019Thomas GadInsiderSell6,000$20.61$123,660.00  
4/11/2019Thomas GadInsiderSell250,000$25.89$6,472,500.00  
9/25/2018Ashu TyagiDirectorBuy430,174$16.00$6,882,784.00  
9/25/2018Moller San Pedro Claus JuanCEOBuy31,250$16.00$500,000.00  
9/21/2018James HealyDirectorBuy500,000$16.00$8,000,000.00  
See Full Table

SEC Filings (Institutional Ownership Changes) for Y-mAbs Therapeutics (NASDAQ:YMAB)

53.20% of Y-mAbs Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Y-mAbs Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in Company
4/5/2021Pacer Advisors Inc.1,812$55K0.0%+137.2%0.004%
3/26/2021Susquehanna International Group LLP6,815$0.34M0.0%+28.2%0.016%
3/12/2021DekaBank Deutsche Girozentrale12,700$0.64M0.0%-4.5%0.029%
2/23/2021Principal Financial Group Inc.16,008$0.79M0.0%+92.8%0.040%
2/19/2021JPMorgan Chase & Co.30,007$1.49M0.0%+1.1%0.074%
2/17/2021Jane Street Group LLC20,607$1.02M0.0%+132.5%0.051%
2/16/2021Squarepoint Ops LLC19,715$0.98M0.0%+26.9%0.049%
2/16/2021Morgan Stanley132,285$6.55M0.0%+75.5%0.327%
2/16/2021Brookfield Asset Management Inc.44,000$2.18M0.0%N/A0.109%
2/16/2021Rice Hall James & Associates LLC100,994$5M0.2%+6.8%0.249%
2/16/2021Nuveen Asset Management LLC138,994$6.88M0.0%+16.5%0.343%
2/16/2021Ashford Capital Management Inc.219,419$10.86M1.1%N/A0.542%
2/16/2021Charles Schwab Investment Management Inc.177,476$8.79M0.0%+3.0%0.438%
2/12/2021Penserra Capital Management LLC930$46K0.0%+171.9%0.002%
2/12/2021Federated Hermes Inc.22,152$1.10M0.0%-79.7%0.055%
2/12/2021Amalgamated Bank4,764$0.24M0.0%N/A0.012%
2/12/2021The Manufacturers Life Insurance Company18,573$0.92M0.0%+4.1%0.046%
2/12/2021Credit Suisse AG27,939$1.38M0.0%-5.2%0.069%
2/12/2021Virtus ETF Advisers LLC11,662$0.58M0.2%+59.6%0.029%
2/11/2021Northern Trust Corp353,099$17.48M0.0%-5.6%0.872%
2/11/2021Barclays PLC12,144$0.60M0.0%-75.0%0.030%
2/11/2021Citigroup Inc.8,141$0.40M0.0%+137.4%0.020%
2/10/2021Rhumbline Advisers38,496$1.91M0.0%+5.3%0.095%
2/10/2021Aviva PLC32,953$1.63M0.0%-44.8%0.081%
2/10/2021Artisan Partners Limited Partnership1,047,416$51.86M0.1%+44.3%2.585%
2/9/2021Wells Fargo & Company MN26,885$1.33M0.0%+63.7%0.066%
2/9/2021Bank of New York Mellon Corp107,759$5.34M0.0%+2.5%0.266%
2/9/2021ProShare Advisors LLC13,012$0.64M0.0%+28.6%0.032%
2/8/2021Vident Investment Advisory LLC31,439$1.56M0.1%+3.3%0.078%
2/8/2021Alliancebernstein L.P.1,010,319$50.02M0.0%+5.3%2.494%
2/8/2021New York State Common Retirement Fund199,599$9.88M0.0%+33.1%0.493%
2/5/2021IndexIQ Advisors LLC8,025$0.40M0.0%+11.5%0.020%
2/5/2021BlackRock Inc.2,418,580$119.74M0.0%+3.1%5.970%
2/5/2021Aperio Group LLC5,685$0.28M0.0%+8.9%0.014%
2/5/2021SG Americas Securities LLC56,712$2.81M0.0%-26.8%0.140%
2/4/2021State of Wisconsin Investment Board48,800$2.42M0.0%-13.6%0.120%
2/2/2021California Public Employees Retirement System67,724$3.35M0.0%-1.9%0.167%
1/22/2021Candriam Luxembourg S.C.A.179,946$8.91M0.1%-1.5%0.444%
1/19/2021DNB Asset Management AS22,559$1.12M0.0%N/A0.056%
12/14/2020Strs Ohio13,800$0.53M0.0%-18.8%0.034%
12/4/2020Sei Investments Co.9,582$0.37M0.0%+13.8%0.024%
11/17/2020California State Teachers Retirement System45,657$1.75M0.0%+1.1%0.113%
11/17/2020Jane Street Group LLC8,864$0.34M0.0%+23.9%0.022%
11/16/2020Squarepoint Ops LLC15,535$0.60M0.0%-4.3%0.038%
11/13/2020Morgan Stanley75,392$2.89M0.0%-8.0%0.186%
11/13/2020First Light Asset Management LLC608,193$23.35M2.4%+0.1%1.501%
11/13/2020ProShare Advisors LLC10,118$0.39M0.0%-2.9%0.025%
11/13/2020Charles Schwab Investment Management Inc.172,240$6.61M0.0%+22.3%0.425%
11/13/2020UBS Asset Management Americas Inc.16,749$0.64M0.0%+6.3%0.041%
11/13/2020Virtus ETF Advisers LLC7,309$0.28M0.1%-12.0%0.018%
11/13/2020Great West Life Assurance Co. Can407,129$3.89M0.0%+28,114.1%1.005%
11/13/2020AXA S.A.189,197$7.26M0.0%-1.0%0.467%
11/12/2020JPMorgan Chase & Co.29,682$1.20M0.0%-5.6%0.073%
11/12/2020Federated Hermes Inc.109,152$4.19M0.0%+22.9%0.269%
11/12/2020Sphera Funds Management LTD.396,521$15.22M1.5%+40.5%0.979%
11/12/2020Skandinaviska Enskilda Banken AB publ1,000$38K0.0%N/A0.002%
11/10/2020State Street Corp1,049,936$40.31M0.0%+9.9%2.624%
11/9/2020SG Americas Securities LLC77,486$2.98M0.0%+1,355.7%0.194%
11/9/2020The Manufacturers Life Insurance Company17,840$0.69M0.0%-1.6%0.045%
11/9/2020Swiss National Bank45,100$1.73M0.0%+1.6%0.113%
11/9/2020State Board of Administration of Florida Retirement System8,715$0.34M0.0%+7.0%0.022%
11/6/2020Sei Investments Co.9,582$0.37M0.0%+13.8%0.024%
11/6/2020BlackRock Inc.2,345,757$90.05M0.0%+1.5%5.862%
11/6/2020Zurcher Kantonalbank Zurich Cantonalbank1,868$72K0.0%+178.4%0.005%
11/5/2020New York State Common Retirement Fund149,980$5.76M0.0%+18.3%0.375%
11/5/2020California Public Employees Retirement System69,024$2.65M0.0%+2.8%0.172%
11/5/2020Alps Advisors Inc.51,029$1.96M0.0%-5.9%0.128%
11/5/2020Wells Fargo & Company MN16,424$0.63M0.0%-10.3%0.041%
11/4/2020American International Group Inc.17,905$0.69M0.0%-2.2%0.045%
11/4/2020Alps Advisors Inc.51,029$1.96M0.0%-5.9%0.128%
10/30/2020BNP Paribas Arbitrage SA7,049$0.27M0.0%+229.9%0.018%
10/29/2020DekaBank Deutsche Girozentrale13,300$0.54M0.0%N/A0.033%
10/26/2020HighMark Wealth Management LLC2,280$88K0.1%+854.0%0.006%
10/20/2020Nisa Investment Advisors LLC1,150$44K0.0%N/A0.003%
10/19/2020Candriam Luxembourg S.C.A.182,704$7.01M0.1%+10.7%0.457%
10/19/2020Pacer Advisors Inc.775$30K0.0%N/A0.002%
9/15/2020Two Sigma Advisers LP79,300$3.43M0.0%+23.1%0.198%
9/15/2020Schonfeld Strategic Advisors LLC14,727$0.64M0.0%-6.7%0.037%
9/4/2020Principal Financial Group Inc.13,649$0.59M0.0%N/A0.034%
9/4/2020Teachers Retirement System of The State of Kentucky20,584$0.89M0.0%-10.5%0.051%
8/25/2020Nuveen Asset Management LLC151,730$6.56M0.0%+40.8%0.379%
8/20/2020Charles Schwab Investment Management Inc.140,881$6.09M0.0%+16.6%0.352%
8/17/2020California State Teachers Retirement System45,144$1.95M0.0%+26.4%0.113%
8/17/2020Jane Street Group LLC7,157$0.31M0.0%N/A0.018%
8/17/2020Perceptive Advisors LLC355,366$15.35M0.2%-32.0%0.888%
8/17/2020Private Advisor Group LLC3,000$0.13M0.0%N/A0.007%
8/14/2020First Light Asset Management LLC607,621$26.25M3.1%N/A1.518%
8/14/2020Bank of America Corp DE69,311$2.99M0.0%+2.5%0.173%
8/14/2020Cormorant Asset Management LP1,574,683$68.03M2.6%-9.1%3.935%
8/14/2020Artal Group S.A.300,030$12.96M0.4%-25.0%0.750%
8/14/2020Vanguard Group Inc.1,239,664$53.55M0.0%+14.6%3.098%
8/14/2020Driehaus Capital Management LLC333,860$14.42M0.4%-24.9%0.834%
8/13/2020FMR LLC1,310,742$56.62M0.0%-5.8%3.276%
8/13/2020Federated Hermes Inc.88,808$3.84M0.0%N/A0.222%
8/13/2020Athanor Capital LP8,460$0.37M0.0%N/A0.021%
8/12/2020Bank of Montreal Can2,477$100K0.0%+2,215.0%0.006%
8/12/2020American International Group Inc.18,311$0.79M0.0%+30.8%0.046%
8/12/2020Goldman Sachs Group Inc.579,878$25.05M0.0%+17.2%1.449%
8/12/2020Barclays PLC52,004$2.25M0.0%+382.4%0.130%
8/12/2020Bank of New York Mellon Corp104,603$4.52M0.0%+22.4%0.261%
Data available starting January 2016

See Full Table
Y-mAbs Therapeutics logo
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Read More

Today's Range

Now: $26.38
$26.14
$28.45

50 Day Range

MA: $34.24
$28.34
$42.73

52 Week Range

Now: $26.38
$26.14
$55.22

Volume

615,992 shs

Average Volume

297,563 shs

Market Capitalization

$1.15 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.36

Who are the company insiders with the largest holdings of Y-mAbs Therapeutics?

Y-mAbs Therapeutics' top insider shareholders include:
  1. Bo Kruse (CFO)
  2. Mahiuddin Ahmed (VP)
  3. Thomas Gad (Insider)
  4. Pedro Claus Juan Moller-San (CEO)
  5. Thomas Gad (Chairman)
  6. David N Gill (Director)
  7. James Healy (Director)
  8. Johan Wedell-Wedellsborg (Director)
  9. Thomas Gad (CEO)
  10. Vignesh Rajah (CMO)

Who are the major institutional investors of Y-mAbs Therapeutics?

Y-mAbs Therapeutics' top institutional shareholders include:
  1. Pacer Advisors Inc. — 0.00%

Which major investors are buying Y-mAbs Therapeutics stock?

Within the last quarter, YMAB stock was bought by institutional investors including:
  1. Pacer Advisors Inc.
Within the previous year, these company insiders have bought Y-mAbs Therapeutics stock:
  1. Bo Kruse (CFO)
  2. Mahiuddin Ahmed (VP)
  3. Thomas Gad (Insider)
Biden Era Ushers In New Breed of Clean-Energy Profit-Stocks
With oil drilling and fracking now dead money, investors are driving Green-Energy stocks to dizzying heights and getting rich along the way. Here’s a brand new clean energy innovator, currently undiscovered at $2 per share, that’s deploying a world’s-first business model with 10X to 20X upside.
Get the details here...
pixel